- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 39/104 - Pseudomonas
Détention brevets de la classe A61K 39/104
Brevets de cette classe: 256
Historique des publications depuis 10 ans
|
22
|
24
|
14
|
24
|
19
|
22
|
17
|
21
|
18
|
8
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Glaxosmithkline Biologicals S.A. | 1603 |
30 |
| Aridis Pharmaceuticals Inc. | 23 |
10 |
| University of Maryland, Baltimore | 1071 |
10 |
| Valneva Austria GmbH | 120 |
9 |
| University of Southern California | 2149 |
8 |
| University of Kansas | 928 |
6 |
| National Research Council of Canada | 1559 |
5 |
| Sichuan University | 634 |
5 |
| Vaxdyn, S.L. | 7 |
5 |
| Evaxion Biotech A/S | 43 |
5 |
| Janssen Pharmaceuticals, Inc. | 432 |
4 |
| Arne Forsgren AB | 5 |
4 |
| Research Institute at Nationwide Children's Hospital | 649 |
4 |
| University of Georgia Research Foundation, Inc. | 1082 |
4 |
| The Regents of the University of California | 20924 |
3 |
| Affinivax, Inc. | 30 |
3 |
| Albany Medical College | 59 |
3 |
| Evaxion Biotech ApS | 21 |
3 |
| Instituto de Salud Carlos III | 44 |
3 |
| Kyoto Prefectural Public University Corporation | 260 |
3 |
| Autres propriétaires | 129 |